The Subcommittee on Consumer Protection and Commerce of the Committee on Energy and Commerce is set to examine the U.S. patent system this morning. Ahead of the hearing – and in honor of #ThrowBackThursay – we are resurfacing a piece by BIO’s Tom DiLenge that helps debunk some of the most…

Keith Ignotz knows the power of a good story. The President & CEO of OcuMedic—an early stage biotech company developing a novel pre-and post-eye surgery treatment to replace eye drops—has made significant inroads telling the OcuMedic story since he assumed his role in early 2018. Some of his…

Whether you come to the Bay Area for the entrepreneurial talent, venture capital investment or biotech innovation, this trifecta conjures the perfect storm for regional economic success. The enduring strength of the Northern California life science cluster attracts small biotech startups, which are…

As the biopharma industry has gained traction on new drug approvals throughout 2019, the financial dollars have followed suit.  According to BIO’s 2019 Emerging Therapeutic Company Trend Report, a record $17.5 billion in venture investment dollars went to emerging therapeutic companies globally in…

In a few short months BIO will be hosting the BIO Investor Forum (#BIF19) for the 17th time. The event’s long history is testament to the continued appetite for partnerships, collaborations and investment in the exciting world of early stage biotech companies on the cusp of medical breakthroughs…

Day three of the 2019 BIO World Congress began by awarding three individuals who have had a profound impact on industrial and agricultural biotechnology. It was a fitting moment because, just like them, #BIOWC19 is bringing people, ideas, and technology together to bolster the bio-economy and…

As the debate on drug pricing continues, our elected leaders will almost certainly adopt policies that will significantly impact—for better or for worse—the lives of many patients. With that in mind, how we do we ensure patients are at the center of this discussion? It starts by recognizing some…

Tomorrow, biotech breakthroughs—such as biofuels that reduce carbon pollution, biodegradable plastics made from plants, or gene-edited crops that can withstand and mitigate the effects of climate change—will take center stage in Des Moines for the 2019 BIO World Congress on Industrial Biotechnology…

Congressman Stiver Continues Call for Sensible Patent Reform While there is consensus across Capitol Hill that patent reform legislation is badly needed, the path to achieving a broadly supported bill remains elusive. This is clearly no easy task, as legislators must curb abusive patent practices,…

Hans Sauer, BIO’s Deputy General Counsel for Intellectual Property, recently testified at the second of three hearings in the Intellectual Property Subcommittee of the Senate Judiciary Committee on the subject of “The State of Patent Eligibility in America.” The hearings are looking at Section 101…